From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts.
Micaela GliozziRoberta MacrìAnna Rita CoppolettaVincenzo MusolinoCristina CarresiMiriam ScicchitanoFrancesca BoscoLorenza GuarnieriAntonio CardamoneStefano RugaFederica ScaranoSaverio NuceraRocco MollaceIrene BavaRosamaria CaminitiMaria SerraJessica MaiuoloErnesto PalmaVincenzo MollacePublished in: Nutrients (2022)
Diabetes is a complex chronic disease, and among the affected patients, cardiovascular disease (CVD)is the most common cause of death. Consequently, the evidence for the cardiovascular benefit of glycaemic control may reduce long-term CVD rates. Over the years, multiple pharmacological approaches aimed at controlling blood glucose levels were unable to significantly reduce diabetes-related cardiovascular events. In this view, a therapeutic strategy combining SGLT2 inhibitors and plant extracts might represent a promising solution. Indeed, countering the main cardiometabolic risk factor using plant extracts could potentiate the cardioprotective action of SGLT2 inhibitors. This review highlights the main molecular mechanisms underlying these beneficial effects that could contribute to the better management of diabetic patients.
Keyphrases
- cardiovascular disease
- cardiovascular events
- blood glucose
- type diabetes
- glycemic control
- heart failure
- end stage renal disease
- coronary artery disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- risk factors
- peritoneal dialysis
- cardiovascular risk factors
- cell wall
- adipose tissue
- weight loss
- blood pressure
- cardiac resynchronization therapy